The first trial in Africa of two combination vaccines to prevent HIV has been halted after researchers concluded it was not working.
The pre-exposure prophylaxis vaccine (PrEPVacc) was being tested on 1,500 people aged between 18 and 40 in Uganda, Tanzania and South Africa.
The African-led trial, which began in December 2020, was stopped last month after an interim review of progress.
Dr Eugene Ruzagira, trial director from the Uganda Virus Research Institute (UVRI) and assistant professor of epidemiology at the London School of Hygiene & Tropical Medicine, said: “Vaccinations to PrEPVacc trial participants have been stopped because an analysis of the data collected so far by our independent data-monitoring committee has led them to conclude that there is little or no chance of demonstrating that the vaccines we are testing are reducing the risk of acquiring HIV.”
Previous trials in South Africa to test the only vaccine that had shown any success in protecting against HIV – the RV144 – developed in Thailand, was stopped in February 2020 after interim results found it was not working.
Prof Pontiano Kaleebu, PrEPVacc’s chief investigator at UVRI, said developing an effective vaccine to prevent HIV infection was “a critical goal for Africa”.
The original article contains 469 words, the summary contains 200 words. Saved 57%. I’m a bot and I’m open source!
This is the best summary I could come up with:
The first trial in Africa of two combination vaccines to prevent HIV has been halted after researchers concluded it was not working.
The pre-exposure prophylaxis vaccine (PrEPVacc) was being tested on 1,500 people aged between 18 and 40 in Uganda, Tanzania and South Africa.
The African-led trial, which began in December 2020, was stopped last month after an interim review of progress.
Dr Eugene Ruzagira, trial director from the Uganda Virus Research Institute (UVRI) and assistant professor of epidemiology at the London School of Hygiene & Tropical Medicine, said: “Vaccinations to PrEPVacc trial participants have been stopped because an analysis of the data collected so far by our independent data-monitoring committee has led them to conclude that there is little or no chance of demonstrating that the vaccines we are testing are reducing the risk of acquiring HIV.”
Previous trials in South Africa to test the only vaccine that had shown any success in protecting against HIV – the RV144 – developed in Thailand, was stopped in February 2020 after interim results found it was not working.
Prof Pontiano Kaleebu, PrEPVacc’s chief investigator at UVRI, said developing an effective vaccine to prevent HIV infection was “a critical goal for Africa”.
The original article contains 469 words, the summary contains 200 words. Saved 57%. I’m a bot and I’m open source!